248924-06-3

Basic information

• Product Name: (4-METHYL-2-PHENYL-1,3-OXAZOL-5-YL)METHANOL
• Synonyms: (4-METHYL-2-PHENYL-1,3-OXAZOL-5-YL)METHANOL
• CAS NO: 248924-06-3
• Molecular Formula: C₁₁H₁₁NO₂
• Molecular Weight: 189.21
• Mol File: 248924-06-3.mol

Chemical Properties

• Boiling Point: 361.1±34.0 °C(Predicted)
• Appearance: /
• Density: 1.176±0.06 g/cm3(Predicted)
• PKA: 13.37±0.10(Predicted)
• CAS DataBase Reference: (4-METHYL-2-PHENYL-1,3-OXAZOL-5-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHYL-2-PHENYL-1,3-OXAZOL-5-YL)METHANOL(248924-06-3)
• EPA Substance Registry System: (4-METHYL-2-PHENYL-1,3-OXAZOL-5-YL)METHANOL(248924-06-3)

Safety Data

• Hazardous Substances Data: 248924-06-3(Hazardous Substances Data)

Upstream product

• 52169-89-8 2-phenyl-4-methyl-oxazole-5-carbonyl chloride 
• 2198-64-3 N-Benzoylalanine 
• 55-21-0 benzamide 
• 22260-83-9 methyl 2-phenyl-4-methyloxazole-5-carboxylate 
• 65-85-0 benzoic acid 
• 4620-46-6 benzoic acid 1-ethoxycarbonyl-2-oxopropyl ester 
• 4620-52-4 Ethyl 4-methyl-2-phenyloxazole-5-carboxylate 

Downstream Products

• 625106-10-7 5-chloromethyl-4-methyl-2-phenyl-oxazole 

Relevant articles and documents

Aromatic heterocyclic small molecule organic compounds and derivatives, preparation method and medical use

The invention discloses heterocyclic aromatic micromolecule organic compounds as shown in the structural formula (I) and derivatives thereof, or hydrates or pharmaceutically acceptable salts, and a preparation method of the corresponding compounds; the invention also discloses an application of the compounds and pharmaceutical compositions containing the compounds to the treatment of various metabolic syndrome-related diseases. The heterocyclic aromatic micromolecule organic compounds of the invention have excellent treatment effect on metabolic syndromes; experiment results show that the compounds may promote secretion of endogenous GLP-1, and are applicable to the preparation of anti-diabetic and fat-reducing candidate medicaments. Aiming at technical problems of easy degradation and short half life of current medicaments for treating diabetes, the invention provides novel, high-efficient micromolecule compounds for promoting secretion of endogenous GLP-1, and the compounds are applicable to the treatment of metabolic syndrome-related diseases such as diabetes, obesity and the like.

TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of liver toxicity by decreasing the lipophilicity, the middle phenyl of TAK-875 was replaced by 11 polar five-membered heteroaromatics. Subsequently, systematic exploration of SAR and application of molecular modeling, leads to the identification of compound 44, which was an excellent FFA1 agonist with robustly hypoglycemic effect both in normal and type 2 diabetic mice, low risks of hypoglycemia and liver toxicity even at the twice molar dose of TAK-875. Meanwhile, two important findings were noted. First, the methyl group in our thiazole series occupied a small hydrophobic subpocket which had no interactions with TAK-875. Furthermore, the agonistic activity revealed a good correlation with the dihedral angle between thiazole core and the terminal benzene ring. These results promote the understanding of ligand-binding pocket and might help to design more promising FFA1 agonists.

A new approach to the synthesis of 2-aryl-4-halomethyl-5-methyl-1,3- oxazoles by highly regioselective direct halogenation with NBS or NCS/MeCN

A simple and efficient method for the synthesis of 2-aryl-4-bromomethyl-5- methyl-1,3-oxazoles 2 and 2-aryl-4-chloromethyl-5-methyl-1,3-oxazoles 3 is described. The reaction of 2-aryl-4,5-dimethyl-1,3-oxazoles 1 with N-bromosuccinimide and N-chlorosuccini

Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme

Novel thiol derivatives of formula I or of the formula Ia wherein the variables have the meanings as defined hereinbefore.